News and Events

Featured Event:

Leaders of the Generic and Biosimilars Industry Have Already Blocked Out Their Calendars for Access! 2019. Have You?

What is the state of our industry? What’s on the horizon? Meet the leaders and decision-makers who are determining the future of generics and biosimilars. Get inspired by new experiences, real talk and fresh ideas during a period of intense challenges and exciting promise. Join 800+ attendees and more than 50+ exhibitors at Access! 2019.  Register now to discover the inspiration, ideas and connections you need to stay on top of the generic and biosimilar industry.

News:

The Biosimilar Council is your source for up-to-date industry news and more. Below you will find event recaps, upcoming event information, news, press releases, and general industry media – all focused on biosimilars.

  • All
  • Events
  • Press Releases
Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
AAM’s Biosimilars Council Announces 3 New Members

WASHINGTON, DC (January 22, 2019) — The Association for Accessible Medicines (AAM) is pleased to announce that three new members have joined its Biosimilars Council:   Accord Healthcare Inc. Fresenius Kabi USA, LLC Sagent Pharmaceuticals, Inc. FDA-approved biosimilars have been estimated to have the potential to save patients and […]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
The Association for Accessible Medicines Urges FDA to Foster Biosimilars Competition, Confidence Under Action Plan

Diverse Stakeholders Say Agency Education Efforts Must Address Misinformation Campaigns to Bolster Patient Trust WASHINGTON, DC (September 21, 2018) — The Association for Accessible Medicines (AAM) today submitted written comments to the Food and Drug […]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
Patient Access to Affordable Medicines: How a Renegotiated NAFTA Could Keep Drug Prices High

Friday, September 14, 2018 Noon–1:00 p.m. 1310 Longworth House Office Building Committee on House Administration Hearing Room On August 31, President Trump notified Congress of his intent to sign a trade agreement with Mexico. This [...]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
Association for Accessible Medicines (AAM) Calls on FDA to Influence Agencies & Congress on Measures to Improve Biosimilar Competition and Lower Costs of Medicine

Stronger Policies to Encourage Biosimilar Market Growth are Essential for America’s Patients, AAM Says (White Oak, MD – Sept. 4, 2018) — Presenting today at the Food and Drug Administration (FDA) public hearing “Facilitating Competition […]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
New Study Finds Patients, Government and Insurance Lose $13.4B in Potential Savings By Brand Drug Companies’ Abuses

Study Finds Costs of Brand Abuses Have Exploded in 4 Years, Harming Patient Access to Affordable Generic and Biosimilar Medicines WASHINGTON DC (September 4, 2018) – Continued efforts to delay patient access to biosimilar and [...]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics

Statement of the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association, and Mexican Association of Generic Medicines on the Announcement U.S.-Mexico Understanding on Biologic Exclusivity The announced trade understanding between the U.S. and Mexico to extend brand name […]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
Breaking Through on Biosimilars: Delivering More-Affordable, Innovative Medicines for America’s Patients

Please join us on Thursday, July 26th at noon for a lunch briefing hosted by the Association for Accessible Medicines (AAM) and its Biosimilars Council to learn more about the promise that biosimilars offer to patients […]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
AAM Statement on FDA’s Biosimilars Action Plan

Agency’s Commitment to Competition, Efficient Development and Approval Process Lauded (Washington, D.C. – July 18, 2018) – The Association for Accessible Medicines (AAM) commends the U.S. Food and Drug Administration (FDA) on its release today [...]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
New Study Finds Biosimilar Competition Can Lower Prescription Drug Costs

Generic and Biosimilars Industry Releases 10th Annual Access and Savings Report Highlights Potential of Biosimilars but Cautions Against Brand Efforts to Thwart Competition (Washington, D.C. – July 10, 2018) —Today, the Biosimilars Council, a division of […]

Biosimilars Council: A Leading Resource on Biosimilars - page-divider-bg
Association for Accessible Medicine’s Biosimilars Council Releases Roadmap for Biosimilars Market Development in U.S.

“Breaking Through on Biosimilars: Delivering More-Affordable, Innovative Medicines for America’s Patients” Recommends Policies to Fulfill Promise of Biosimilars (Washington, D.C. –  May 30, 2018) – The Biosimilars Council, a division of the Association for Accessible […]